Short Interest in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Declines By 60.4%

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 1,900 shares, a decline of 60.4% from the February 28th total of 4,800 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average trading volume of 9,500 shares, the short-interest ratio is presently 0.2 days.

CollPlant Biotechnologies Stock Down 2.6 %

Shares of CLGN traded down $0.07 during trading on Friday, reaching $2.63. 3,279 shares of the company traded hands, compared to its average volume of 10,561. The stock has a market cap of $30.13 million, a PE ratio of -1.71 and a beta of 1.07. CollPlant Biotechnologies has a twelve month low of $2.56 and a twelve month high of $6.75. The stock has a 50-day simple moving average of $3.47 and a 200-day simple moving average of $3.95.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its quarterly earnings data on Wednesday, March 26th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.08. CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. The business had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $0.36 million. On average, equities research analysts predict that CollPlant Biotechnologies will post -1.44 EPS for the current year.

Institutional Trading of CollPlant Biotechnologies

Hedge funds have recently made changes to their positions in the business. AMH Equity Ltd increased its stake in CollPlant Biotechnologies by 17.4% during the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after buying an additional 17,295 shares during the period. Benjamin Edwards Inc. acquired a new stake in CollPlant Biotechnologies in the 3rd quarter valued at about $112,000. Renaissance Technologies LLC purchased a new position in CollPlant Biotechnologies in the fourth quarter worth approximately $38,000. Finally, Wells Fargo & Company MN lifted its position in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock worth $30,000 after purchasing an additional 4,405 shares during the last quarter. Institutional investors and hedge funds own 21.69% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a report on Friday, November 29th. D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of CollPlant Biotechnologies in a report on Thursday.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.